Meritage Swallows $2M

1/28/11

San Diego-based drug developer Meritage Pharma raised $2 million in a round of equity-based financing planned to total $5.5 million, an SEC filing indicates. Meritage is out to develop a treatment for a little-known ailment  called eosinophilic esophagitis, in which an allergic reaction causes a patient’s esophagus to swell, sometimes to the point where food becomes lodged in it. Previous investors in Meritage, which launched a trial of its treatment in January 2009, include Domain Associates, Latterell Venture Partners, and The Vertical Group.

By posting a comment, you agree to our terms and conditions.